Pelthos Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Pelthos Therapeutics Inc. (NYSE American: PTHS) is a commercial-stage specialty biopharmaceutical company focused on acquiring, launching, and scaling innovative dermatology and cutaneous infectious disease products. The company was formed in 2025 through a merger between LNHC, Inc. (a subsidiary of Ligand Pharmaceuticals) and Channel Therapeutics Corporation. Pelthos' commercial strategy is anchored by its flagship product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, which is the first and only FDA-approved topical prescription medication for molluscum contagiosum that can be administered at home by patients or caregivers. The company also advances a pipeline of topical candidates utilizing its proprietary nitric oxide-based technology platform, NITRICIL™.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the commercialization of ZELSUVMI™ (berdazimer) topical gel, 10.3%, the first and only FDA-approved at-home prescription treatment for molluscum contagiosum.
Expected impact: Establishment of a leading market share in the pediatric dermatology market, supported by an expanded sales force of 64 territory managers.
Acquiring and preparing to relaunch complementary FDA-approved topical products (Xepi and Xeglyze) that target pediatric and dermatology communities.
Expected impact: Allows the company to leverage its existing commercial infrastructure and sales force to promote multiple brands with high call overlap and minimal incremental overhead.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of U.S. commercialization rights from Biofrontera Inc. and Ferrer Internacional S.A. to add a complementary FDA-approved topical treatment for impetigo to the Pelthos dermatology portfolio.
Financial impact: Upfront payments of $3.0 million to Biofrontera and $1.2 million to Ferrer, with additional milestone and royalty payments based on net sales.
Acquisition of worldwide rights from Hatchtech Pty Ltd. to add an FDA-approved topical treatment for head lice to the commercial portfolio.
Financial impact: Flat $1.8 million purchase price with no future milestone, royalty, or other payments owed to the seller.
Strategic Partnerships
Ligand spun out Pelthos and maintains a 56% ownership stake. Ligand provides ongoing strategic support and holds representation on the Pelthos Board of Directors.
Terms: Ligand is entitled to a 13% royalty on worldwide net sales of ZELSUVMI and up to $5 million in commercial sales milestones.